Join us at our Capital Markets Day on Thursday, February 5, 2026, in central Stockholm and online.
The Capital Markets Day will provide investors, analysts, and financial media with an update on Cereno Scientific’s clinical development programs, strategic priorities, and growth ambitions. The program will feature presentations by members of Cereno Scientific’s management team, as well as contributions from external speakers with relevant scientific and clinical expertise.
The program will focus on Cereno Scientific’s lead candidate CS1, which is being developed as a disease-modifying treatment for pulmonary arterial hypertension (PAH). CS1 has been granted Orphan Drug Designation (ODD) in both the U.S. and Europe and earlier this year received Fast Track designation from the U.S. Food and Drug Administration (FDA), underscoring its potential to address a serious disease with high unmet medical need. The company recently received regulatory clearance from the FDA for its planned Phase IIb trial of CS1, with patient recruitment expected to commence in Q2 2026. The event will also offer deeper insights into the significant unmet medical needs within the disease, as well as the scientific rationale underpinning its pioneering therapeutic approach based on epigenetic modulation through histone deacetylase inhibition (HDACi), with the potential to modify the underlying drivers of disease rather than solely addressing symptoms.
Further details regarding the agenda, speakers, venue, and registration will be communicated closer to the event.